Top Page
China Resources Pharmaceutical Group Ltd.
(Frankfurt:3320)
China Resources Pharmaceutical Group Ltd. (3320) vs. iShares MSCI Hong Kong ETF (EWH)
China Resources Pharmaceutical Group Ltd. Business Overview & Revenue Model
China Resources Pharmaceutical Group Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 274.18B | 270.40B | 254.11B | 236.81B | 200.42B |
| Gross Profit | 43.30B | 42.18B | 39.13B | 35.38B | 32.29B |
| EBITDA | 15.45B | 15.43B | 15.47B | 11.95B | 12.47B |
| Net Income | 3.57B | 3.85B | 3.50B | 3.08B | 2.78B |
Balance Sheet | |||||
| Total Assets | 274.28B | 271.48B | 243.93B | 248.56B | 209.37B |
| Cash, Cash Equivalents and Short-Term Investments | 17.48B | 59.27B | 32.52B | 37.32B | 52.34B |
| Total Debt | 73.43B | 62.16B | 63.85B | 82.59B | 55.20B |
| Total Liabilities | 169.90B | 169.20B | 150.24B | 152.69B | 128.69B |
| Stockholders Equity | 51.34B | 50.60B | 49.56B | 50.98B | 46.47B |
Cash Flow | |||||
| Free Cash Flow | 14.55B | 12.42B | 7.54B | 8.32B | 4.06B |
| Operating Cash Flow | 17.55B | 15.55B | 10.90B | 11.22B | 6.28B |
| Investing Cash Flow | -8.89B | -2.07B | -3.30B | -8.83B | -2.02B |
| Financing Cash Flow | -16.84B | -4.07B | -9.00B | 5.31B | -3.60B |
China Resources Pharmaceutical Group Ltd. Technical Analysis
China Resources Pharmaceutical Group Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $43.00B | 9.65 | 7.86% | 7.32% | 1.13% | -13.53% | |
| ― | $34.35B | 12.45 | 14.91% | 3.88% | -0.45% | 9.00% | |
| ― | HK$29.00B | 13.76 | 12.65% | 3.20% | 10.56% | -13.58% | |
| ― | HK$30.72B | 10.10 | 5.90% | 2.70% | ― | ― | |
| ― | $80.78B | 18.09 | 6.75% | 1.52% | -1.12% | 76.16% | |
| ― | $31.96B | 17.86 | 10.01% | 2.25% | 11.78% | 19.06% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
China Resources Pharmaceutical Group Ltd. Corporate Events
CR Boya Bio-pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the nine months ending September 30, 2025. The company experienced a revenue increase to RMB 1.47 billion compared to the previous year, but net profit decreased to RMB 343 million. Additionally, there was a significant reduction in cash and cash equivalents, highlighting potential liquidity challenges. The financials, prepared under PRC accounting standards, have not been audited and may be subject to adjustments, urging caution among shareholders and investors.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
CR Sanjiu reported its unaudited financial results for the nine months ending September 30, 2025, showing a revenue increase to RMB 21.99 billion from RMB 19.74 billion in the previous year, despite a decline in net profit to RMB 2.90 billion from RMB 3.24 billion. The financials highlight a net decrease in cash and cash equivalents and a significant rise in total assets and liabilities, indicating potential adjustments during auditing, and advising caution for shareholders and investors.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
Jiangzhong Pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the nine months ending September 30, 2025. The company saw a slight decrease in revenue compared to the previous year, but net profit increased, indicating improved operational efficiency. The financials show a positive cash flow and an increase in total assets, suggesting a stable financial position. However, the figures have not been audited and may be subject to adjustments, prompting caution among investors.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
KPC Pharmaceuticals, Inc., partially owned by China Resources Pharmaceutical Group Ltd., reported a decrease in revenue and net profit for the nine months ending September 30, 2025, compared to the previous year. The financial results indicate a net decrease in cash and cash equivalents, highlighting potential challenges in liquidity. The announcement advises caution for shareholders and potential investors due to the unaudited nature of the financials, which may require adjustments.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the nine months ending September 30, 2025. The company saw an increase in revenue and net profit compared to the previous year, with revenue reaching RMB 4.77 billion and net profit at RMB 1.28 billion. Despite a decrease in total assets, the company experienced a positive net increase in cash and cash equivalents, indicating improved liquidity. Stakeholders are advised to exercise caution as the financials are unaudited and may require adjustments.
CR Double-Crane, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the nine months ending September 30, 2025. The company experienced a slight decline in revenue and net profit compared to the previous year, with revenue at RMB 8.28 billion and net profit at RMB 1.39 billion. Despite a decrease in cash and cash equivalents, the company saw an increase in total assets and owner’s equity, indicating a stable financial position. Shareholders and investors are advised to exercise caution as the financials are unaudited and may require adjustments.
Tasly Pharmaceutical reported its unaudited financial results for the nine months ending September 30, 2025, showing a slight decrease in revenue but a notable increase in net profit compared to the previous year. The financials reveal a positive cash flow change and a stable asset base, suggesting a solid financial position for Tasly, which could impact China Resources Pharmaceutical Group’s overall market standing and investor confidence.
China Resources Pharmaceutical Group Ltd. announced the successful issuance of the first tranche of its 2025 corporate bonds in China, amounting to RMB1.1 billion with a 1.82% annual coupon rate. The proceeds will be used for various operational and developmental purposes, including debt repayment and investment in scientific and technological innovations, potentially enhancing the company’s operational capabilities and market position.
China Resources Pharmaceutical Group Ltd. announced a change in its executive leadership, with Mdm. Deng Rong resigning as an executive director and member of the executive committee, while continuing her role as CFO. Concurrently, Mr. Liu Changan has been appointed as an executive director and member of the executive committee, bringing his experience from previous roles within the company and other organizations. These changes are expected to maintain the company’s strategic direction and stability, ensuring continued focus on its growth and operational goals.
China Resources Pharmaceutical Group Ltd. has announced the list of its board of directors, highlighting the roles and functions of each member. This announcement provides clarity on the leadership structure, which is crucial for stakeholders to understand the company’s governance and strategic direction.
China Resources Pharmaceutical Group Ltd. reported its unaudited interim results for the first half of 2025, showing a slight increase in revenue to RMB 131.87 billion compared to the previous year. Despite the revenue growth, the company’s net profit decreased to RMB 5.05 billion, attributed to higher selling and distribution expenses, and other losses. The results highlight challenges in maintaining profitability amidst rising operational costs, which could impact the company’s market positioning and stakeholder confidence.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group Ltd. announced an interim dividend of RMB 0.072 per share for the six months ending June 30, 2025, with the option for shareholders to receive the dividend in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.0957. This announcement reflects the company’s stable financial performance and commitment to delivering shareholder value, potentially enhancing its market position and investor confidence.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group Ltd. announced significant changes in its executive leadership, effective August 26, 2025. Mr. Tao Ran has resigned from his roles as executive director and member of the Executive Committee, while Mr. Cheng Jie has been appointed as the new executive director, president, and member of both the Executive and Corporate Governance Committees. These changes are expected to influence the company’s strategic direction, leveraging Mr. Cheng’s extensive experience in the pharmaceutical sector and his leadership roles within the company’s subsidiaries.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group Ltd. has announced the composition of its board of directors and their respective roles within the organization. This announcement is significant as it outlines the leadership structure, which is crucial for the company’s strategic direction and governance, potentially impacting its operational efficiency and stakeholder confidence.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
CR Boya Bio-pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported a 12.51% increase in revenue for the first half of 2025 compared to the same period in 2024. However, the company experienced a significant decline in net profit attributable to shareholders by 28.68%, along with a drastic reduction in net cash flow from operating activities by 96.72%, indicating potential challenges in operational efficiency and profitability.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
CR Double-Crane, a subsidiary of China Resources Pharmaceutical Group, reported a slight increase in total assets and net assets for the first half of 2025, despite a decrease in revenue and net profit compared to the previous year. The financial results indicate a challenging period with a decline in net profit and cash flow from operating activities, reflecting the company’s need to address operational efficiencies and market conditions.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the first half of 2025, showing a revenue increase of 11.02% and a net profit rise of 10.74% compared to the previous year. The financial performance indicates a stable growth trajectory, with improvements in net cash flow from operating activities and earnings per share, reflecting positively on the company’s operational efficiency and market positioning.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
Jiangzhong Pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported a slight increase in total assets and net assets for the first half of 2025, despite a decline in revenue. The company saw a notable rise in net profit and operating cash flow, indicating improved operational efficiency and profitability, which could positively impact its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
CR Sanjiu reported its unaudited financial results for the first half of 2025, showing a 4.99% increase in revenue to RMB 14.81 billion, but a significant drop in net profit by 24.31% to RMB 1.82 billion. Despite the revenue growth, the decline in net profit and earnings per share indicates challenges in maintaining profitability, which could impact investor confidence and market positioning.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
KPC Pharmaceuticals, a subsidiary of China Resources Pharmaceutical Group, released its unaudited financial results for the first half of 2025, showing a decline in revenue and net profit compared to the previous year. Despite a slight increase in total assets, the company experienced a decrease in net assets attributable to shareholders and a reduction in net cash flow from operating activities, indicating challenges in maintaining profitability and operational efficiency.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
Tasly Pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the first half of 2025, showing a slight decline in revenue by 1.91% compared to the same period in 2024. Despite the revenue drop, the net profit attributable to shareholders increased by 16.97%, indicating improved profitability. However, the net profit after extraordinary gains or losses decreased by 12.87%, and the net cash flow from operating activities fell by 10.95%. The company’s total assets and net assets attributable to shareholders saw modest increases of 3.15% and 3.98%, respectively, reflecting a stable financial position.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group Ltd. is in discussions to form a fund with a projected size of RMB500 million, aimed at investing in high-growth enterprises in synthetic biology, innovative drugs, and biotechnology. The company’s proposed capital commitment is approximately RMB123 million, representing 24.6% of the total fund commitment, with Shenzhen CR Capital expected to manage the fund. The formation of the fund involves a connected transaction due to the involvement of Hanwei Huayou Shantou, a connected person under the company’s controlling shareholder, CRH.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group Ltd. has announced that its board of directors will meet on August 26, 2025, to consider and approve the interim results for the first half of the year and potentially declare an interim dividend. This meeting is significant as it will provide insights into the company’s financial health and could impact shareholder value and market positioning.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.